fdx2 Antibody

What is FDX2 and why is it important in research?

FDX2 is a mitochondrial protein encoded by the FDX2 gene, with a reported length of 186 amino acid residues and a molecular mass of approximately 19.9 kDa in humans . It contains a 2Fe-2S ferredoxin-type domain and is essential for heme A and Fe/S protein biosynthesis . The protein is primarily localized in the mitochondrial matrix and is widely expressed throughout the body, with highest levels in testis, kidney, and brain . FDX2 belongs to the Adrenodoxin/putidaredoxin protein family and plays a crucial role in electron transport chains .

Research interest in FDX2 has intensified due to its implication in mitochondrial myopathy, episodic, with optic atrophy and reversible leukoencephalopathy (MEOAL) . This autosomal recessive neuromuscular disorder is characterized by childhood onset of recurrent episodes of proximal weakness and myalgia, often precipitated by exercise, infections, or low temperature . Recent studies have also revealed that FDX2 is essential for preventing cellular senescence, apoptosis, or ferroptosis, depending on cellular context .

What are the key considerations when selecting FDX2 antibodies for research?

When selecting FDX2 antibodies, researchers should consider:

• Specificity: FDX2 shares structural similarity with FDX1 (adrenodoxin), so antibodies should be validated for specificity against both isoforms . Consider antibodies raised against unique epitopes of FDX2.

• Applications: Different experimental techniques require antibodies with specific properties. For instance, Western blotting may require denaturation-resistant epitope recognition, while immunofluorescence requires antibodies that recognize native protein conformations .

• Species reactivity: FDX2 orthologs have been identified in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken . Select antibodies that recognize your species of interest.

• Validation data: Look for antibodies with comprehensive validation, including positive and negative controls, and demonstration of specificity in multiple applications .

• Clone type: For monoclonal antibodies like CBXF-1736, consider whether the specific epitope recognized is appropriate for your application .

What are the optimal protocols for Western blotting detection of FDX2?

For effective Western blot detection of FDX2, researchers should consider:

• Sample preparation: Since FDX2 is mitochondrial, subcellular fractionation may improve detection. Tissue or cells should be lysed in RIPA buffer, with protein concentration determined using appropriate assays such as the Pierce 660 nm protein assay .

• Gel selection: Use 6-18% gradient SDS-PAGE gels for optimal separation of the relatively small (19.9 kDa) FDX2 protein .

• Transfer conditions: Due to FDX2's small size, use semi-dry transfer methods with PVDF membranes for better retention.

• Blocking: 5% non-fat milk in TBS-T for 1 hour at room temperature has been effectively used in studies of FDX2 .

• Primary antibody: Incubate with anti-FDX2 antibody (such as affinity-purified antibodies used in Sheftel et al., 2010) at the manufacturer's recommended dilution, typically overnight at 4°C .

• Appropriate controls: Include both positive controls (tissues known to express FDX2 such as kidney or testis) and loading controls such as VDAC, F1 α/β subunits of complex V, tubulin, or actin .

• Validation: Confirm specificity by running samples from FDX2-knockout models if available, or samples with known FDX2 deficiency as negative controls .

How can immunofluorescence techniques be optimized for FDX2 detection?

For immunofluorescence studies of FDX2:

• Fixation: Use 4% paraformaldehyde for 15 minutes at room temperature to preserve mitochondrial structure.

• Permeabilization: Gentle detergents like 0.1% Triton X-100 are recommended to maintain mitochondrial integrity while allowing antibody access.

• Mitochondrial co-staining: Use established mitochondrial markers (MitoTracker dyes, TOMM20, or COX IV antibodies) for co-localization studies to confirm the mitochondrial localization of FDX2 .

• Antibody selection: Choose antibodies specifically validated for immunofluorescence applications, like the mouse anti-FDX2 recombinant antibody (CBXF-1736) .

• Signal validation: Confirm specificity through siRNA knockdown controls or comparison with tissues from FDX2-deficient models.

• Confocal microscopy: High-resolution imaging is essential for accurately determining submitochondrial localization of FDX2 in the mitochondrial matrix.

How can FDX2 antibodies be used to study iron-sulfur cluster biosynthesis?

FDX2 plays a crucial role in iron-sulfur (Fe/S) cluster biosynthesis, distinct from FDX1. To study this process:

• Co-immunoprecipitation: Use FDX2 antibodies to pull down protein complexes involved in Fe/S cluster assembly, such as interactions with the cysteine desulfurase complex NFS1-ISD11-ACP1 (NIA) and frataxin (FXN) .

• Proximity ligation assays: Investigate direct protein-protein interactions between FDX2 and other components of the Fe/S cluster assembly machinery.

• Activity assays: After immunoprecipitation of FDX2, measure its ability to support [2Fe-2S] cluster synthesis on the scaffold protein ISCU2 through circular dichroism (CD) spectroscopy .

• Biochemical fractionation: Use FDX2 antibodies in combination with size exclusion chromatography to identify different assembly states of Fe/S biogenesis complexes.

• Comparative analysis: Use both FDX1 and FDX2 antibodies to demonstrate their functional differences in Fe/S protein biogenesis. Research has shown that even a fivefold excess of FDX1 over NIA does not support [2Fe-2S] cluster synthesis, while FDX2 is effective at equimolar amounts .

How can researchers use FDX2 antibodies to investigate oxidative stress mechanisms?

FDX2 deficiency has been linked to increased reactive oxygen species (ROS) production. To study this relationship:

• Dual labeling: Combine FDX2 immunostaining with ROS-sensitive dyes to correlate FDX2 levels with ROS production at the cellular level .

• Cellular compartment analysis: Use fractionation followed by immunoblotting to measure FDX2 levels in different mitochondrial subcompartments during oxidative stress.

• Time-course experiments: Monitor FDX2 levels via Western blotting before and after oxidative stress induction to determine if expression changes are part of the cellular stress response.

• Rescue experiments: In FDX2-depleted cells showing increased ROS (as seen in studies where FDX2 depletion led to significantly higher levels of cellular and mitochondrial ROS), reintroduce wild-type FDX2 and measure the effect on ROS levels using both antibody detection of FDX2 and ROS measurement .

• Glutathione status correlation: Combine FDX2 antibody detection with measurements of reduced (GSH) and oxidized (GSSG) glutathione to establish relationships between FDX2 function and redox homeostasis .

How can FDX2 antibodies contribute to understanding mitochondrial myopathies?

Mutations in FDX2 are associated with mitochondrial myopathy with episodic symptoms. To study these conditions:

• Patient sample analysis: Use FDX2 antibodies to assess protein levels in muscle biopsies from patients with suspected mitochondrial disorders. This approach identified severe reduction of FDX2 levels in patients with the p.P144L mutation compared to controls .

• Mutation impact assessment: Compare wild-type and mutant FDX2 protein levels using antibodies to determine if specific mutations affect protein stability, as demonstrated for the p.P144L variant, which maintains normal mRNA expression but shows dramatically reduced protein levels .

• Tissue-specific expression analysis: Use FDX2 antibodies to examine expression patterns across different tissues to understand the tissue-specific manifestations of FDX2-related disorders .

• Functional correlations: Combine FDX2 immunostaining with markers of mitochondrial function (such as complex activity stains or markers of mitochondrial dynamics) to correlate FDX2 deficiency with specific mitochondrial dysfunctions .

• Treatment monitoring: In potential therapeutic trials, monitor FDX2 protein levels using antibodies to assess the efficacy of interventions aimed at restoring FDX2 function or levels.

What approaches can be used to study FDX2-related cell death mechanisms?

FDX2 depletion can lead to different cell death outcomes depending on cellular context:

• Apoptosis detection: Use FDX2 antibodies alongside apoptotic markers (cleaved caspase 3, PARP cleavage, annexin V binding) to determine if FDX2 deficiency triggers apoptotic pathways in specific cell types .

• Ferroptosis analysis: In cells prone to ferroptosis, combine FDX2 immunostaining with lipid peroxidation markers and iron chelation rescue experiments to establish the connection between FDX2 deficiency and ferroptotic cell death .

• Cellular senescence studies: Use FDX2 antibodies in combination with senescence markers (β-galactosidase activity, p16, p21) to examine the role of FDX2 in preventing cellular senescence .

• Genetic background effects: Analyze FDX2 levels in relation to p53 status, as research has shown different cell death outcomes in p53-wild-type versus p53-knockout backgrounds upon FDX2 depletion .

• Rescue experiments: Reintroduce FDX2 in depleted cells and use antibodies to confirm expression while monitoring cell death markers to establish causal relationships.

How can researchers differentiate between FDX1 and FDX2 in experimental settings?

Differentiating between the two mitochondrial ferredoxin isoforms is critical:

• Isoform-specific antibodies: Use antibodies that recognize unique epitopes not conserved between FDX1 and FDX2 .

• Western blot verification: Confirm antibody specificity by testing against recombinant FDX1 and FDX2 proteins side by side.

• Knockout/knockdown controls: Use samples from FDX1 or FDX2 knockdown/knockout models to verify antibody specificity .

• RT-qPCR correlation: Combine protein detection with isoform-specific RT-qPCR (using primers spanning exon junctions, such as those for FDX2 spanning the exon 4-5 junction) to confirm the identity of the detected protein .

• Tissue distribution analysis: FDX1 and FDX2 show distinct tissue distribution patterns, which can be used as a reference point for validation. FDX2 is widely expressed, while FDX1 shows more restricted expression despite widespread mRNA distribution .

What are the most common technical challenges when using FDX2 antibodies and how can they be addressed?

Researchers may encounter several technical challenges:

• Low signal intensity: FDX2 may be expressed at low levels in some tissues. Enhance detection by:

  • Using signal amplification methods like tyramide signal amplification for immunohistochemistry

  • Optimizing protein extraction from mitochondria with specialized buffers

  • Increasing antibody incubation time or concentration

• Non-specific binding: Distinguish from specific signal by:

  • Including FDX2-knockout or knockdown controls

  • Performing peptide competition assays with the immunizing peptide

  • Using secondary-only controls to identify background

• Variability between antibody lots: Minimize impact by:

  • Purchasing sufficient antibody for complete experimental series

  • Validating each new lot against previous lots

  • Including consistent positive controls across experiments

• Detection in fixed tissues: For challenging samples:

  • Optimize antigen retrieval methods (citrate buffer, pH 6.0 is often effective)

  • Test multiple fixation protocols to identify optimal conditions

  • Consider using fresh frozen sections rather than paraffin-embedded samples

• Quantification accuracy: Ensure reliable quantification by:

  • Using multiple loading controls (mitochondrial and cytosolic) as shown in studies with F1 α/β, VDAC, tubulin, and actin

  • Establishing linear range of detection for each antibody

  • Performing technical and biological replicates